CF
IBRX icon

Copperwynd Financial’s ImmunityBio IBRX Stock Holding History

Copperwynd Financial’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,087
Closed -$51.4K – 149
2024
Q4 		$51.4K Buy
20,087
+10,000
+99% +$41.7K 0.01% 135
2024
Q3 		$37.5K Sell
10,087
-5,900
-37% -$27.3K 0.01% 141
2024
Q2 		$82.3K Sell
15,987
-6,008
-27% -$39.6K 0.03% 145
2024
Q1 		$118K Buy
21,995
+6,295
+40% +$28.5K 0.04% 139
2023
Q4 		$78.8K Buy
+15,700
New +$49.3K 0.03% 136

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Copperwynd Financial's IBRX Position: Q1 2025 in Review

Copperwynd Financial sold out of ImmunityBio (IBRX) in Q1 2025, closing a stake of 20,087 shares — an estimated $51.4K sold.

Copperwynd Financial first reported a position in IBRX in Q4 2023 and held it in 5 quarters. The position peaked at $118K in Q1 2024. 210 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

  • Copperwynd Financial reported no remaining ImmunityBio position as of Q1 2025 after selling out during the quarter.
  • Copperwynd Financial sold 20,087 ImmunityBio shares in Q1 2025, an estimated $51.4K.
  • Copperwynd Financial first reported a position in ImmunityBio in Q4 2023 and held it in 5 quarters.
  • Copperwynd Financial's ImmunityBio position peaked at $118K in Q1 2024.
  • 210 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on Copperwynd Financial's 13F filing for Q1 2025, filed 5 May 2025.